• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Harari Eliyahou Et Al

    3/26/26 9:46:58 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CV alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    HARARI ELIYAHOU ET AL

    (Last)(First)(Middle)
    225 CHARCOT

    (Street)
    SAN JOSE CALIFORNIA 95131

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/16/2026
    3. Issuer Name and Ticker or Trading Symbol
    CapsoVision, Inc [ CV ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock878,448D
    Common Stock3,186,901IBy trust.(1)
    Common Stock517,759IBy trust.(2)
    Common Stock517,759IBy trust.(3)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. The securities are held by the Harari Family Trust, for which the Reporting Person, together with his wife, are trustees.
    2. The securities are held by Harari 2010 Children Remainder Trust - MH, for which the Reporting Person, together with his wife, are trustees.
    3. The securities are held by Harari 2010 Children Remainder Trust - DAH, for which the Reporting Person, together with his wife, are trustees.
    /s/ Peter Bergman, Attorney-in-Fact for Eliyahou Harari03/26/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $CV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CV

    DatePrice TargetRatingAnalyst
    7/28/2025$5.00Speculative Buy
    The Benchmark Company
    7/28/2025$6.00Buy
    Roth Capital
    More analyst ratings

    $CV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Tsai Chen Lung bought $83 worth of shares (20 units at $4.17) (SEC Form 4)

    4/A - CapsoVision, Inc (0001378325) (Issuer)

    2/6/26 4:37:48 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on CapsoVision with a new price target

    The Benchmark Company initiated coverage of CapsoVision with a rating of Speculative Buy and set a new price target of $5.00

    7/28/25 8:55:56 AM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Roth Capital initiated coverage on CapsoVision with a new price target

    Roth Capital initiated coverage of CapsoVision with a rating of Buy and set a new price target of $6.00

    7/28/25 8:55:14 AM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CV
    SEC Filings

    View All

    SEC Form 10-K filed by CapsoVision Inc.

    10-K - CapsoVision, Inc (0001378325) (Filer)

    3/26/26 4:44:07 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - CapsoVision, Inc (0001378325) (Filer)

    3/26/26 4:08:52 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Regulation FD Disclosure

    8-K - CapsoVision, Inc (0001378325) (Filer)

    3/20/26 8:04:37 AM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results

    SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Fourth quarter 2025 revenue was $3.9 million, a 13% increase over the fourth quarter of 2024. Full year 2025 revenue was $13.6 million, a 15% increase compared to full year 2024.New accounts grew 16% in the fourth quarter of 2025 over the comparable quarter in 2024. Full year 2025 new accounts grew 21% compared to full year 2024.CapsoCam Plus® used by over 161,000 patients as of

    3/26/26 4:05:00 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CapsoVision Announces $14 Million Private Placement Financing

    SARATOGA, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (the "Company") (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced the closing of a $14 million private placement in public equity financing (the "Private Placement") pursuant to a securities purchase agreement entered into by the Company with selected accredited investors on March 16, 2026 for such investors to purchase shares (the "Shares") of common stock of the Company. Pursuant to the securities purchase agreement, the Company has agreed to sell 2,867,089 shares of common stock of the Company, with par value $0.001 per

    3/20/26 8:00:00 AM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026

    SARATOGA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release fourth quarter and full year 2025 financial results on Thursday, March 26, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and refere

    3/12/26 4:05:00 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Shen Ching Hang

    3 - CapsoVision, Inc (0001378325) (Issuer)

    3/30/26 3:52:57 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Harari Eliyahou Et Al

    3 - CapsoVision, Inc (0001378325) (Issuer)

    3/26/26 9:46:58 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Tsai Chen Lung

    4 - CapsoVision, Inc (0001378325) (Issuer)

    3/23/26 6:29:25 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CV
    Financials

    Live finance-specific insights

    View All

    CapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026

    SARATOGA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release fourth quarter and full year 2025 financial results on Thursday, March 26, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and refere

    3/12/26 4:05:00 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CapsoVision to Release Third Quarter 2025 Financial Results on Thursday, November 13, 2025

    SARATOGA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release third quarter 2025 financial results on Thursday, November 13, 2025, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and referencing conferen

    10/30/25 4:05:00 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025

    - Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET - SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence ("AI") technologies that are deployed in its capsule endoscopy solutions, today announced that the company will release second quarter 2025 financial results on Thursday, August 14, 2025, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the c

    7/31/25 4:05:00 PM ET
    $CV
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care